Webinar | February 26, 2018

Improve Your Phase I Success Rate: Fast Early Technology Screening for Poorly Bioavailable Molecules

Source: Catalent

It is, increasingly, essential to examine and rank multiple delivery options in parallel, to collect data about the relative dose capability, PK enhancement and manufacturability in order to select drug candidates to advance to clinical Phase 1. This parallel screening strategy de-risks the early drug development and increases the success rate for later stages as compared with the linear model where the predicable failures from iterative approach make the drug development process longer and costlier. This webinar provides an overview of a parallel formulation feasibility assessment approach that is designed to reveal the most suitable pathway to enhance bioavailability and accelerate development.

Learn more about:

  • Understand the classification of poorly bioavailable compounds using the Developability Classification System.
  • Understand how a structured, high throughput and parallel screening approach can expedite preclinical development.
  • Learn various scenarios were enabling technologies such as lipid based formulation, solid dispersion and particle size engineering can be applied.